S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Innoviva Stock Price, News & Analysis (NASDAQ:INVA)

$14.39
+0.40 (+2.86%)
(As of 12/4/2023 ET)
Compare
Today's Range
$13.94
$14.44
50-Day Range
$12.32
$14.39
52-Week Range
$10.64
$14.44
Volume
670,241 shs
Average Volume
657,444 shs
Market Capitalization
$922.21 million
P/E Ratio
32.71
Dividend Yield
N/A
Price Target
$15.17

Innoviva MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5.4% Upside
$15.17 Price Target
Short Interest
Bearish
15.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.64mentions of Innoviva in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

916th out of 952 stocks

Pharmaceutical Preparations Industry

421st out of 434 stocks


INVA stock logo

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

INVA Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Innoviva: A Lot Of Moving Parts
Innoviva (NASDAQ: INVA)
Innoviva's Reward Isn't Worth The Risk
Innoviva Announces Retirement of Board Chairman
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
101
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$15.17
High Stock Price Target
$22.50
Low Stock Price Target
$10.00
Potential Upside/Downside
+5.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$213.92 million
Pretax Margin
23.49%

Debt

Sales & Book Value

Annual Sales
$331.34 million
Cash Flow
$2.39 per share
Book Value
$8.11 per share

Miscellaneous

Free Float
63,190,000
Market Cap
$920.33 million
Optionable
Optionable
Beta
0.52

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














INVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price target for 2024?

3 Wall Street analysts have issued twelve-month price targets for Innoviva's shares. Their INVA share price targets range from $10.00 to $22.50. On average, they anticipate the company's share price to reach $15.17 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2023?

Innoviva's stock was trading at $13.25 at the start of the year. Since then, INVA shares have increased by 8.6% and is now trading at $14.39.
View the best growth stocks for 2023 here
.

Are investors shorting Innoviva?

Innoviva saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 9,610,000 shares, an increase of 7.1% from the October 31st total of 8,970,000 shares. Based on an average daily trading volume, of 668,000 shares, the short-interest ratio is presently 14.4 days. Approximately 15.2% of the company's stock are sold short.
View Innoviva's Short Interest
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.98 EPS for the quarter. The biotechnology company had revenue of $67.26 million for the quarter. Innoviva had a trailing twelve-month return on equity of 24.11% and a net margin of 17.17%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different retail and institutional investors. Top institutional investors include Westfield Capital Management Co. LP (3.19%), Charles Schwab Investment Management Inc. (1.23%), American Century Companies Inc. (1.20%), Bank of New York Mellon Corp (1.12%), Northern Trust Corp (1.13%) and Invesco Ltd. (1.03%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -